Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | iC9.CAR-CSPG4 T-cells |
| Synonyms | |
| Therapy Description |
iC9.CAR-CSPG4 T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CSPG4 and also express inducible caspase-9, which potentially induce killing of tumor cells expressing CSPG4 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| iC9.CAR-CSPG4 T-cells | Autologous anti-CSPG4 CAR-iC9-expressing T-lymphocytes | iC9.CAR-CSPG4 T-cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CSPG4 and also express inducible caspase-9, which potentially induce killing of tumor cells expressing CSPG4 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T-cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |